A Study to Compare Pharmacokinetic and Safety of TRS003 to China-approved Bevacizumab and US-licensed Avastin®

Inclusion Criteria: * Healthy, male participants, 18-55 years old with no significant medical history, and in good health as determined by detailed medical history, full physical examination, vital signs, 12-lead electrocardiogram (ECG), urinalysis and laboratory tests at screening. * Body mass index of 17.5-30.5 kg/m\^2 and body weight of 50-95 kg. * Protocol-specified hematology, coagulation, blood chemistry and urinalysis within the laboratory normal range at screening, unless deemed not clinically significant by the Investigator. * Participants must have adequate organ function according to the following laboratory values: 1. Bone marrow function (absolute neutrophil count ≥1500/mm\^3 and platelet count ≥100,000/mm\^3) 2. Adequate liver function \[alanine aminotransferase (ALT) ≤3 × upper limit normal (ULN) and alkaline phosphatase ≤2 × ULN, total bilirubin ≤1.5 mg/dL\] 3. Adequate renal function creatinine clearance ≥60 mL/min based on Cockcroft-Gault equation * Participants must agree to use an acceptable form of birth control throughout the study and for at least 18 weeks after the study is over. Exclusion Criteria: * Participants unable to give voluntary informed consent. * Evidence or history of clinically significant disease, cancer other than adequately treated basal cell or squamous cell carcinoma of the skin. * Participants on anticoagulant drugs, anemic or with known bleeding diatheses. * Participants with a history of severe, uncontrolled hypertension, heart disease, cerebrovascular incidents, gastrointestinal bleeding, hemoptysis, frequent epistaxis or gingival bleeding. * History clinically significant orthostatic hypotension, fainting spells, vasovagal syncope. * Uncontrolled severe hypertension (140/90 mm Hg). * Previous treatment with an anti-VEGF antibody or any other antibody or protein targeting the VEGF receptor. * Use of any prescription, investigational drugs, herbal supplements or nonprescription drugs within 1 month or 5 half-lives (whichever is longer) prior to the first dose, or dietary supplements within 1 week prior to the first dose. If needed, paracetamol/acetaminophen may be used, but must be documented in the Concomitant medications/Significant non-drug therapies page of the case report form (CRF). * Serious unhealed wound, cutaneous ulcer or bone fracture at the time of screening. * Major surgery or major dental procedure or significant traumatic injury within 2 months prior to screening, or any planned surgery or procedure within 3 months after investigational treatment administration. Participants must have recovered from all acute surgery- or trauma-related complications. * Participant's medical and family history of recent or recurrent thromboembolism or other clotting and coagulation disorders. * Donated blood over 400 mL within 3 months. * History of relevant and clinically significant intra-abdominal inflammation, gastrointestinal perforation or gall bladder perforation. * History of severe allergic or anaphylactic reaction to a therapeutic drug or severe seasonal allergies. * Recent (within the last three \[3\] years) and/or recurrent history of acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or not treated). * A positive hepatitis B, hepatitis C or HIV tests at screening indicative of a current or past infection. * Current use of tobacco or nicotine-containing products. Concomitant treatment was given only if Investigator believes strictly necessary and should be documented. * Current use of any biologic drugs.